# Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Source: https://onco.cc/trials/nct07018050/  
OnCo record `nct07018050` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of QLS32015, Pomalidomide, Dexamethasone in multiple myeloma, run by Qilu Pharmaceutical Co., Ltd., now recruiting.

## Summary

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma is a phase 2 interventional study registered as NCT07018050 by Qilu Pharmaceutical Co., Ltd., with 160 participants planned, started 2025-09-12 and due to reach its primary completion in 2027-11. Interventions recorded: QLS32015, Pomalidomide, Dexamethasone, QL2109 or Daratumumab, Bortezomib. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07018050
- Phase: 2
- Setting: A Multicenter, Open-Label Phase II Study to Evaluate QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT07018050: https://clinicaltrials.gov/study/NCT07018050

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/), [QLS32015](https://onco.cc/drugs/qls32015/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07018050.json